ArticleFrontiers in pharmacology2024
The association between continuous polypharmacy and hospitalization, emergency department visits, and death in older adults: a nationwide large cohort study.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Polypharmacy Thresholds that Best Predict Emergency Room Visits and Mortality in Older Adults: A Population-Based Study in Québec, Canada.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2026Article
- Assessing Associations of Three Types of Higher-Risk Medication Use and Mortality in Older Adults.Journal of the American Geriatrics Society · 2026Article
- Explainable Machine Learning for Predicting Adverse Drug Events in Older Adults with Polypharmacy: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Conditions identified by common comprehensive geriatric assessment measures and subsequent acute care among adults with SLE.Lupus science & medicine · 2026Article
- Alcohol use and in-hospital complications in patients aged ≥ 80 years admitted to Internal medicine: a multicentre observational study in Spain.Aging clinical and experimental research · 2026Observational
- Responsiveness and minimum important change of the Pharmacotherapeutic Symptom Evaluation-20-Australian version: a tool for measuring changes in medicine-related symptoms over time.International journal of clinical pharmacy · 2026Article
- Burden of geriatric and cognitive disorders and the impact of integrated care models on morbidity, functional decline, and health service utilization among older adults.Frontiers in medicine · 2026Article
- Assessment of Functional Capacity and Its Sociodemographic and Health Determinants in Older Adults from a Region of Peru.Risk management and healthcare policy · 2026Article
- Balancing polypharmacy and comorbidity management: cardiovascular health.Current opinion in HIV and AIDS · 2025Review
- Determinants of medical costs in patients with and without fractures using Korean Senior Cohort Study.Scientific reports · 2025Article
- Examining the Effect of Polypharmacy on Quality of Life and Frailty in Older Adults from the Perspective of Community-Based Rehabilitation.Healthcare (Basel, Switzerland) · 2025Article
- Pioneering hospital-at-home in Taiwan: early clinical outcomes from the first cohort of nursing home older adults.Frontiers in health services · 2025Article
- Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018.PloS one · 2025Article
- Knowledge, attitudes, and practices of inpatients with chronic cardiovascular comorbidities regarding polypharmacy: a cross-sectional study.Frontiers in pharmacology · 2025Article
- Impact of Polypharmacy on Perioperative Outcomes of Robot-assisted Laparoscopic Partial Nephrectomy for Small Renal Masses.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the association between continuous polypharmacy and hospitalization, emergency department (ED) visits, and death. Methods: This retrospective study utilized 6,443,896 patients aged between 65 and 84 years of National Health Insurance claims data from 2016 to 2018. Polypharmacy and excessive polypharmacy were defined as the concurrent use of 5 or more and 10 or more medications, respectively, for durations of both 90 days or more and 180 days or more within a 1-year observation period. The primary outcome measures included all-cause hospitalization, ED visits, and mortality. Multiple logistic regression models were used adjusting for patients' general characteristics, comorbidities, and history of hospitalization or ED visits. Results: Among 2,693,897 patients aged 65-84 years who had used medicines for 180 days or more (2,955,755 patients taking medicines for 90 days or more), the adverse outcomes were as follows: 20.5% (20.3%) experienced hospitalization, 10.9% (10.8%) visited the ED, and 1% (1%) died, respectively. In patients who exhibited polypharmacy for more than 180 days, the adjusted odds ratio of adverse outcomes was 1.32 (95% confidence interval [CI], 1.31-1.33) for hospitalization, 1.32 (95% CI, 1.31-1.33) for ED visits, 1.63 (95% CI, 1.59-1.67) for death, and that in excessive polypharmacy patients for more than 180 days was 1.85 for hospitalization, 1.92 for ED visits, and 2.57 for death, compared to non-polypharmacy patients. Conclusion: Our results suggest that polypharmacy in older adults might lead to negative health consequences. Thus, interventions to optimize polypharmacy may need to be implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.